drugset / Trial / NCT07546669
Efficacy of Zoster Vaccination in Glioblastoma Patients
Phase 4
Not yet recruiting
230 enrolled
University Hospital, Essen
Karolinska Institutet · collabLeiden University Medical Center · collabUniversitätsklinikum Hamburg-Eppendorf · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
In modern practice a trimodality treatment has emerged as standard of care for histologically confirmed glioblastoma. We hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by irradiation therapy and chemotherapy of patients with glioblastoma will lead to a superior local control, overall and progression free survival. In an additional experimental setting based on patient preference the immunological effectiveness of the adoptive transfer of autologous polyclonal cytomegalovirus (CMV) specific T cells will be examined.
Timeline
- Start
- 2027-01-02
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | autologous CMV-specific T-cells | Cell therapy | 2e+07 unknown | Intravenous |
| Subject | herpes zoster vaccine | Vaccine | — | — |